Skip to content

A Multiple-center Study on the Effect of Different Ways of Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With More Than 50% Solid Components

Zhongshan Hospital

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04581122
Enrollment
1500
Registered
2020-10-09
Start date
2020-09-01
Completion date
2028-12-31
Last updated
2020-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Progression

Brief summary

A multiple-center study on the effect of different ways of lymph node dissection on the prognosis of less than 3cm ground glass nodules with more than solid components

Interventions

PROCEDURELymphadenectomy

Patients with ground glass nodules smaller than 3cm and with more than 50%solid components would randomly assigned to selective lymphadenectomy group or systematic lymph node dissection group

Sponsors

Shanghai Zhongshan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Aged between 18 and 75 years; 2. GGO is diagnosed by lung CT and failure to subside after 3 months (the patient having been re-examined by thin-section CT); 3. The maximum diameter of the GGO is smaller than 3cm; 4. The maximum diameter of the solid component in the GGO is more than 50%; 5. The patient is able to undergo the lobectomy 6. The patient is able to understand and comply with the study and has provided written informed consent.

Exclusion criteria

\- Patients meeting any of the following criteria are not eligible for this trial: 1. Patients with a history of using immunosuppressive or hormonal drugs; 2. Patients receiving radiotherapy or chemotherapy; 3. Patients who fail to comply with our follow-up strategy; 4. Other situations that are not in conformity with the standards and requirements of this trial.

Design outcomes

Primary

MeasureTime frameDescription
overall survival (OS)5 yearsfive year overall survival

Countries

China

Contacts

Primary ContactJiang Wei, Dr
jiang.wei1@zs-hospital.sh.cn86-21-64041990

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026